1034975-35-3

Basic information

• Product Name: tert-butyl 2-amino-4-(4-methylpiperazin-1-yl)benzoate
• Synonyms: tert-butyl 2-amino-4-(4-methylpiperazin-1-yl)benzoate
• CAS NO: 1034975-35-3
• Molecular Weight: 291.393
• EINECS: -0
• Mol File: 1034975-35-3.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: tert-butyl 2-amino-4-(4-methylpiperazin-1-yl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 2-amino-4-(4-methylpiperazin-1-yl)benzoate(1034975-35-3)
• EPA Substance Registry System: tert-butyl 2-amino-4-(4-methylpiperazin-1-yl)benzoate(1034975-35-3)

Safety Data

• Hazardous Substances Data: 1034975-35-3(Hazardous Substances Data)

Usage

General Description

Tert-butyl 2-amino-4-(4-methylpiperazin-1-yl)benzoate is a chemical compound with the molecular formula C17H27N3O2. It is a derivative of the compound benzoate, and contains an amino group and a piperazine group. The tert-butyl group is a bulky hydrophobic group that can affect the compound's solubility and stability. tert-butyl 2-amino-4-(4-methylpiperazin-1-yl)benzoate may have potential applications in pharmaceutical research and drug development due to its structural features and potential biological activity. Further research is needed to fully understand and explore the properties and potential uses of tert-butyl 2-amino-4-(4-methylpiperazin-1-yl)benzoate.

Upstream product

• 942271-60-5 tert-butyl 4-fluoro-2-nitrobenzoate 
• 109-01-3 1-methyl-piperazine 
• 942271-61-6 tert-butyl 4-(4-methylpiperazin-1-yl)-2-nitrobenzoate 

Downstream Products

• 1034975-40-0 tert-butyl 4-(4-methylpiperazin-1-yl)-2-(tetrahydropyran-4-ylamino)benzoate 
• 1392150-68-3 tert-butyl 2-((4,4-difluorocyclohexyl)amino)-4-(4-methylpiperazin-1-yl)benzoate 
• 1392150-69-4 tert-butyl 2-(N-(4,4-difluorocyclohexyl)-2,2,2-trifluoroacetamido)-4-(4-methylpiperazin-1-yl)benzoate 
• 1108743-60-7 N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)benzamide 
• 1108745-38-5 N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)benzamide 
• 1034976-52-7 4-(4-methylpiperazin-1-yl)-2-[(tetrahydropyran-4-yl)-(2,2,2-trifluoroacetyl)amino]benzoyl chloride 

Relevant articles and documents

Preparation method and application of broad-spectrum anticancer drug entrectinib intermediate

The invention relates to the field of preparation of 2-amino-4-(4-methyl-1-piperazine) tert-butyl benzoate, in particular to a preparation method and application of a broad-spectrum anticancer drug emtricitinib intermediate. The preparation method of the broad-spectrum anticancer drug emtricitinib intermediate comprises the step of reacting 2-nitro-4-(4-methyl-1-piperazinyl)-tert-butyl benzoate with sulfur-containing alkali metal at the temperature of 5-100 DEG C in a solvent in the presence of inorganic alkali to obtain the product. Based on the low-cost and easily available sodium hydrosulfite reduction process, the use of a controlled dangerous hydrogenation process and special equipment is avoided, the reaction condition is mild, the stability is good, the production cost is greatly reduced. the preparation method is environmentally friendly, economical and suitable for large-scale production.

HETEROCYCLIC DERIVATIVES MODULATING ACTIVITY OF CERTAIN PROTEIN KINASES

The present invention relates to novel heterocyclic derivatives having general formula (I) and their therapeutic use for diseases such as cancer, inflammation, pain, autoimmune diseases or neurodegenerative diseases like Alzheimer's or Parkinson's disease that can be treated by modulation of certain protein kinases. Compounds of formula (I) can be used for treatment of patients who do not respond to kinase inhibition therapy that comprises currently available medications.

Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk

The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture, as well as pharmaceutical composition comprising such a compound, for use in the treatment of a cancer associated with the overexpression of at least one Trk protein.